Skip to main content

Press releases 2011

2012-12-12
Moberg Derma AB (OMX: MOB) today announced that it has entered into an exclusive distribution agreement for Emtrix®, a novel, over-the-counter product for the local treatment of fingernail and toenail fungal infections (onychomycosis), in Canada. Under the terms of the agreement, Paladin has been granted the exclusive rights to market and sell Emtrix® in Canada. Emtrix® is an over-the-counter (OTC), topical product with a unique mechanism of action that generates visible improvements within 2-4 weeks of treatment. Further details or financial terms of the transaction were not disclosed.
2012-11-30
The number of shares and votes in Moberg Derma AB (publ) has increased by 1,733,552 to 10,812,572 during November 2012. Therefore, there are in total 10,812,572 shares and votes in the company as of November 30th, 2012.
2012-11-28
Under the authorization from the extraordinary general meeting on November 19th, 2012, the Board of Directors of Moberg Derma AB (publ) resolved on November 27th, 2012, to execute an issue in kind of up to 825 652 shares, and thereby complete the acquisition of Alterna LLC.
2012-11-07
Moberg Derma AB (OMX: MOB) today announces that it has received the final results from a phase II study of MOB-015 in patients with onychomycosis. The clinical efficacy was unsatisfactory, and the company has therefore decided to initiate a new study with an improved formulation.
2012-10-26

As previously announced, Moberg Derma is conducting a directed share issue in connection with the company’s acquisition of its U.S. distributor Alterna LLC. In conjunction with subscription of the new shares, delivery will initially take place through a share lending agreement entered into between the issuing agent and Östersjöstiftelsen.

2012-10-25
CONTINUED STRONG GROWTH AND ACQUISITION IN THE U.S.
2012-10-25
The Board of Moberg Derma AB (“Moberg Derma”, the “Company” or the “Group”) has decided to acquire its US distributor, Alterna LLC. Through the acquisition, Moberg Derma will gain access to a well-developed distribution network in the US for non-prescription drugs (OTC) and a portfolio of established brands, including the rights to Kerasal Nail™ (Nalox™ in Sweden). In order to carry out the transaction, the Board has resolved to issue new shares with deviation from the shareholders’ preferential rights, as well as to propose an extraordinary general meeting to approve the transaction and a proposed issue in kind.
2012-10-22
In accordance with the decision taken at Moberg Derma’s Annual General Meeting 2012 the Chairman of the Board has contacted the largest shareholders of the company to appoint a Nomination Committee before the Annual General Meeting 2013.
2012-09-06
Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 97 patients with Actinic Keratosis (AK) on the head or face for the on-going Limtop phase II study. The aim is to evaluate the efficacy and safety of three different dose regimens of Limtop. The results are expected in the first half of 2013. Limtop is an innovative formulation of imiquimod for the treatment of actinic keratosis, genital warts and basal cell cancer. The objective is a product with short treatment duration, improved safety profile and similar or better efficacy than that of competing preparations. ”We are very pleased that patient recruitment has been successfully completed and that the study is proceeding according to plan. Limtop may enable field treatment and reduce the risk of side effects”, says Peter Wolpert, CEO and founder of Moberg Derma.
2012-08-28
EUROPEAN LAUNCHES DRIVES CONTINUED STRONG GROWTH
2012-08-16
Moberg Derma (STO: MOB) expects to reach all remaining milestones in its agreement with Meda related to Nalox™ in 2012, generating a further MSEK 15.5. This assessment is based on a successful launch in several markets in Europe, including Germany and France.
2012-07-10
The number of Walmart stores selling Kerasal® Nail in U.S. rises from 1 300 to 3 500 stores in August 2012. Walmart is one of the leading U.S. retail chains and the increased distribution is an important step towards Moberg Derma’s goal of Kerasal® Nail becoming the market leader in the U.S..
2012-06-25
Moberg Derma AB (STO:MOB) has entered into a distribution agreement with Ana Darou P.J.S. for Nalox™/Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Ana Darou is granted exclusive rights to market and sell Nalox™/Emtrix® in Iran. Moberg Derma assumes production and supply responsibility.
2012-05-02
The German Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase II trial for Limtop. The aim is to evaluate the efficacy and safety of three different dose regimens of Limtop in a study involving 96 patients with Actinic Keratosis (AK) on the head or face. The results are expected in the first half of 2013. The approval was granted following positive results from a phase I study on 30 healthy volunteers who were treated daily for 21 days. No serious treatment-related adverse events were observed.
2012-04-23
Moberg Derma AB’s Annual General Meeting took place on Monday, April 23, 2012 in the company´s premises in Bromma.
2012-04-23
CONTINUED STRONG GROWTH AND PROFITABILITY
2012-04-23
CONTINUED STRONG GROWTH AND PROFITABILITY
2012-03-27
Moberg Derma AB (STO:MOB) has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox™//Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Pharmaplan is granted exclusive rights to market and sell Nalox™ /Emtrix® in South Africa. Moberg Derma assumes production and supply responsibility.
2012-03-23
This notice replaces the previous notice of Annual General Meeting in Moberg Derma AB (publ). The proposal on the Employee Stock Option Plan 2012:1, to be addressed under item 15 on the agenda for the Annual General Meeting, is corrected as to the number of employee stock options than can be allotted and the number of warrants that can be issued. Shareholders in Moberg Derma AB (publ) (reg. no. 556697-7426) (the ”Company”) are hereby convened to the Annual General Meeting on Monday, April 23, 2012 at 5.30 p.m. in the Company’s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.
2012-03-20
The Nomination Committee of Moberg Derma AB (STO: MOB) was established by decision of the annual general meeting 2011 and comprises Per-Olof Edin, chairman of the Nomination Committee, appointed by Östersjöstiftelsen, Conny Bogentoft, appointed by SIX SIS AG, Oscar Ahlgren, appointed by Mohammed Al Amoudi, and Mats Pettersson, chairman of the board of directors. Today the Nomination Committee announces its proposals to Moberg Derma’s annual general meeting on 23 April 2012. The proposals will also be presented in the notice to attend the meeting.
2012-03-13
The Board of Moberg Derma AB (OMX: MOB) assessed that the company has the potential to show profitability already full-year 2012 based on continued positive development and revenue growth. Moberg Derma therefore updates its financial goals. Its short-term goal of operative profit and cash flow for the full-year 2013 is omitted, since it is assessed that profitability can be achieved already 2012. The long term (3-5 years) financial goal remains - to achieve an operating margin before depreciation and amortization (operating profit as a percentage of sales) of 25% with continued strong growth.
2012-03-13
The Board of Moberg Derma AB (OMX: MOB) considers it as probable that future taxable profit will be available and can be utilized against unutilized tax losses. This tax receivable is reported both in the income statement and balance sheet, resulting in a positive impact first quarter 2012 by SEK 31.8 million. The Company has outstanding tax loss carryforward of 120.8 million.
2012-03-09
The German- Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to initiate a clinical phase I trial for Limtop. Limtop is an innovative formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma. The objective is a product with short treatment duration, an improved safety profile and an efficacy similar to or better than that of competing preparations. 
2012-02-09
Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be completed and results are expected by the end of the year.
2012-02-09
STRONG REVENUE GROWTH AND SIGNIFICANTLY IMPROVED EARNINGS
2012-01-17
Moberg Derma AB (STO: MOB) has hired Lena Pereswetoff-Morath as Vice President Pharmaceutical Innovation & Development. Lena comes from a similar position at Orexo and has extensive experience in drug development, e.g. from Biolipox and AstraZeneca.